EAST BRUNSWICK, N.J.–(BUSINESS WIRE)–Rising Pharmaceuticals, an affiliate of Rising Pharma Holdings Inc., announced the approval, launch and immediate commercial availability of Edetate calcium disodium injection. This launch will address a critical commercial shortage of this important therapy in the United States.
“The approval and launch of Rising’s Edetate calcium disodium injection opens access to a critical treatment option for patients exposed to lead poisoning, and further demonstrates Rising’s commitment to addressing product supply shortages for the patients who need them”
Rising’s Edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
“The approval and launch of Rising’s Edetate calcium disodium injection opens access to a critical treatment option for patients exposed to lead poisoning, and further demonstrates Rising’s commitment to addressing product supply shortages for the patients who need them,” said Ira Baeringer, Chief Operating Officer, Rising Pharmaceuticals.
With over 182 commercialized generic medicines and over 620 active SKUs, Rising has one of the largest portfolios of any generic pharmaceutical company in the U.S. market. Through an extensive global network of manufacturing facilities, Rising supplies almost 9 billion doses of generic medicine to the market annually.
What is Edetate calcium disodium for injection?
Edetate calcium disodium for injection is a prescription medicine, used to treat both children and adults with acute and chronic lead poisoning:
Edetate calcium disodium injection should not be given during periods of anuria (lack of urine production), nor to patients with active renal disease or hepatitis.
IMPORTANT SAFETY INFORMATION
Edetate calcium disodium injection is capable of producing toxic effects which can be fatal. Lead encephalopathy is relatively rare in adults, but occurs more often in pediatric patients in whom it may be incipient and thus overlooked. The mortality rate in pediatric patients has been high. Patients with lead encephalopathy and cerebral edema may experience a lethal increase in intracranial pressure following intravenous infusion; the intramuscular route is preferred for these patients. In cases where the intravenous route is necessary, avoid rapid infusion. The dosage schedule should be followed and at no time should the recommended daily dose be exceeded.
About Rising Pharmaceuticals
Rising Pharmaceuticals is a leading provider of generic and specialty-branded pharmaceuticals in the U.S. Rising focuses on the development, regulatory, and commercial aspects of the product life cycle while outsourcing manufacturing to its network of strategic CMO and CDO partners. The Company is based in New Brunswick, New Jersey. For more information about the Company, please visit www.risingpharma.com.